Literature DB >> 26460874

Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.

Stacy Loeb1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26460874      PMCID： PMC4827854          DOI： 10.1016/j.eururo.2015.07.065

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  5 in total

1.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.

Authors:  Paul R Womble; James E Montie; Zaojun Ye; Susan M Linsell; Brian R Lane; David C Miller
Journal:  Eur Urol       Date:  2014-08-24       Impact factor: 20.096

2.  Physician variation in management of low-risk prostate cancer: a population-based cohort study.

Authors:  Karen E Hoffman; Jiangong Niu; Yu Shen; Jing Jiang; John W Davis; Jeri Kim; Deborah A Kuban; George H Perkins; Jay B Shah; Grace L Smith; Robert J Volk; Thomas A Buchholz; Sharon H Giordano; Benjamin D Smith
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

Review 3.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

4.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

5.  Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

Authors:  Adam C Reese; Patricia Landis; Misop Han; Jonathan I Epstein; H Ballentine Carter
Journal:  J Urol       Date:  2013-05-13       Impact factor: 7.450
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.